A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Artio Medical Closes $28M in Additional Series A Financing

Funding to launch commercial sales team in US and continue development of best-in-class product pipeline

Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, today announced the closing of $28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised to date to $74 million.

Funds will be used to support US commercialization efforts for the recently cleared Solus Gold™ Embolization Device and to accelerate the development of Artio’s broad portfolio of products, including expanding the Company’s engineering and manufacturing capabilities.

Artio is currently developing ten products for the peripheral vascular market, including the Solus Gold™ and Solus Flex™ Embolization Devices for peripheral vessel occlusion and the Amplifi™ Vein Dilation System which is designed to prepare hemodialysis patients for successful arteriovenous fistula vascular access site creation.

Artio Medical is also currently developing four products for the neurovascular market, including the Endura™ Embolization System comprising a detachable balloon and coils for the treatment of saccular brain aneurysms.

“We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio,” stated Joseph McConnell, Vice President of Finance and Business Operations at Artio. “We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people. This new capital will help Artio expand our team and scale our operations to deliver on that mission.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Noze states the grant will fund a groundbreaking clinical study aimed at detecting TB in high-burden countries, using the company's DiagNoze® — a handheld breathalyzer designed for the real-time detection and screening of various medical conditions, including infectious diseases such as TB.
Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."

By using this website you agree to accept Medical Device News Magazine Privacy Policy